This article first appeared on GuruFocus. Novo Nordisk A/S (NVO, Financials), the Danish drugmaker behind Wegovy and Ozempic, is facing a problem that may arrive well before its patent cliff. Warning! GuruFocus has detected 4 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator.NVO GF Value chart Morgan Stanley downgraded the stock to Sell after its latest survey suggested Eli Lilly could keep taking share in the fast-growing obesity and diabetes market. Shares fell about 2% early Friday. The pressure is already showing up in prescriptions.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.